


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1654
Sh

In re Application of: PLOUG, et al.
Serial No.: 09/743,329
Filed: December 26, 2001
For: PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR...
Confirmation No.: 9896

Art Unit: 1654
Examiner: GUPTA, A.
Washington, D.C.
Atty.'s Docket: PLOUG=1
Date: June 30, 2005



U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314
Sir:

Transmitted herewith is an [XX] Amendment [] in the above-identified application.
[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been previously asserted.
[] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
[] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	Small Entity				Other Than a Small Entity			
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Additional Fee		Rate	Additional Fee
Total	35	Minus	58	0		x 25	\$		x 50	\$
Indep.	1	Minus	3	0		x100	\$		x200	\$
First Presentation of Multiple Dependent Claim						180	\$		+360	\$
TOTAL ADDITIONAL CLAIMS FEE							\$		Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity		Other Than Small Entity	
Response Filed Within		Response Filed Within	
[] First	- \$ 60.00	[] First	- \$ 120.00
[] Second	- \$ 225.00	[] Second	- \$ 450.00
[] Third	- \$ 510.00	[] Third	- \$1020.00
[] Fourth	- \$ 795.00	[] Fourth	- \$1590.00
[] Fifth	- \$1080.00	[] Fifth	- \$2160.00

[] Less fees (\$) already paid for months extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____. A duplicate copy of this sheet is attached.

[] A check in the amount of \$_____ is attached (check no. _____).

[] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$_____ is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

By:
IVER P. COOPER
Registration No. 28,005



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1654
)	
PLOUG, et al.)	Examiner: CHISM, B.
)	
Serial No.: 09/743,329)	Washington, D.C.
)	
Filed: December 26, 2001)	June 30, 2005
)	
For: PEPTIDE ANTAGONISTS OF)	Docket No.: PLOUG=1
THE HUMAN UROKINASE)	
RECEPTOR AND METHOD...)	Confirmation No.: 9896

AMENDMENT UNDER RULE 1.115

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

S i r :

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.